Harrow, Inc. · NASDAQ:HROW
Harrow — Investor Day (September 2025)
117 slides from Harrow's investor day presentation, Sep 26, 2025
Slide 1: Investor & Analyst Day September 2025
Investor & Analyst Day September 2025 i» HARROW
Slide 2: Opening Remarks
Opening Remarks Mike Biega, VP of Investor Relations and Communications Investor &
Slide 3: Safe Harbor
Safe Harbor This contains “ d-looki "as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking These are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncer
Slide 4: Agenda
Agenda Topic Welcome & Opening Remarks Harrow’s Purpose & Vision Financial Update Harrow's Pipeline Products MELT-300 Development Overview and Potential An Expert's P ive on P dati Commercial Vision VEVYE Overview An Expert's Perspective of Dry Eye & VEVYE Access for All Programs TRIESENCE Expansion
Slide 5: Harrow Leadership Here Today
Harrow Leadership Here Today @ 2 & Mark L. Baum Andrew R. Boll Amir H. Shojaei Prashanth S. Annavajjhala John P. Saharek Chief Executive Officer, President & Chief Financial Chief Scientific Officer Chief of Staff to the CEO ), Harrow's Chairman of the Board, Officer, Founder ImprimisRx Subsidiary &
Slide 6: Thought Leaders Here Today
ff Thought Leaders Here Today Larry Dillaha, M.D. Maggie Jeffries, Paul Karpecki, Raj N. Patel, MD Seenu Hariprasad, MD MD, FASA OD, FAAO
Slide 7: Purpose & Vision
Purpose & Vision Mark L. Baum, Chairman and CEO Investor & Analyst Day | Sepiember 2029 HARROW’
Slide 8: Our Vision is to Become the Next Great US Ophthalmic Company
Our Vision is to Become the Next Great US Ophthalmic Company y + “Harrow was founded in 2012 with $1 million of capital and $1 tillion of determination” ... Mark L Baum + Baum and Boll lead all business development activities, supported by Harrow SMEs + Disciplined; fast-moving and dynamic; seize gr
Slide 9: Harrow's Purpose is to Provide Ophthalmic Disease Management Solutions
Harrow’s Purpose is to Provide Ophthalmic Disease Management Solutions for the North American Market Safe and Effective Accessible and Affordable Enhance Patient Compli Improve Clinical Outcomes From Zero to Market Leader: Focused on Eyecare; a Stable Operating Cost Disciplined Acquisition Approac S
Slide 10: Harrow's Ophthalmic Disease Management Solutions
Harrow’'s Ophthalmic Disease Management Solutions DRY EYE DISEASE THEE: atin sibel S AUVWhid AUVANODaS SURGICAL RARE & SPECIALTY PRODUCTS Natacyn’ ™Verkazia’ Soca Losporine ophthalmic Setettonmeteim emulsion 0.19% BYQLovI” ILEVRO. | ILEVRO. ©Maxitrol’ —Flarex’ opto Fe} | epatenacophtalmic finns laut
Slide 11: Today's Acquisition News
Today’s Acquisition News elt S PHARMACEUTICALS® History - founded as a Harrow subsidiary to seek FDA-approval of MELT-300, inspired by ImprimisRx's MKO Melt compounded formulation; deconsolidated from Harrow’s balance sheet; externally funded and managed; Phase 3 data supports a 2026 NDA filing Proj
Slide 12: Commitment to Supporting Mission Trips
Commitment to Supporting Mission Trips See Intl Eye Doctors of Lancaster Nevis Eye Care Health in Sight Missions (Honduras) April 2024 (Afica) October 2024 (West Indies) November 2024 (Honduras) February 2025 During 2024, Harrow's donations helped approximately 17,000 in 2025, Harrow has committed d
Slide 13: Financials
Financials Andrew Boll, President and CFO Investor &
Slide 14: Harrow's Approach to Business Development
Harrow’s Approach io Business Development Harrow’s Business Development Team is Mark and Andrew, supported by SME Leadership re GOs @) res eae Product & Exec’ Long-Term ecic Fit Market Profile Pfegration Value Creati + Focus on acquisitions in markets we know deeply and have strong conviction in + P
Slide 15: Debt Refinancing and Credit Facility
Debt Refinancing and Credit Facility Credit Rating MoopY's Unsecured Notes Total $250M Matty 5S years itchRatings Coupon 8.625% Revolver Unused Line Fee: 0.25% Int. Rate: SOFR + 1.25% to 1.75% Debt Refinancing: Total Refinanced + expenses + interest $240M FIFTH THIRD New Cash to Bal. Sheet $10M Undr
Slide 16: Harrow Consolidated Revenues
NG ee Harrow Consolidated Revenues jin incuscnas) "25 Guidance > $280,000 22% Growth »y $72,476 A H2: $29M HI: $19.9 20 2 22 23 24 25 ow Investor Analyst Day | september205 HARROW
Slide 17: Harrow's 2027 Goal of $250M Quarterly Revenue
Harrow’s 2027 Goal of $250M* Quarterly Revenue Key Product Family Revenue Drivers @4 2027 Targeted Quarterly Revenue Execution Elements vév (Cyclosporine dphthatnic soln) 01% $75M VAFA driving NRx growth Best-in-class attributes & refillrates Gross-to-net improves upon increased coverage and refills
Slide 18: Pipeline Products
Pipeline Products Amir Shojaei, Chief Scientific Officer Investor & Analyst Day | September 2025 HARROW
Slide 19: Introduction: Amir Shojaei
Introduction Amir Shojaei Chief Scientific Officer Amir H. Shojaei was named Harrow’s Chief Scientific Officer in January 2025, bringing with him nearly 30 years of experience in the life sciences sector. A leader in clinical regulatory affairs, and the commerciaiization of biopharmaceutical and bio
Slide 20: Harrow's Approach to Clinical Development
Harrow’s Approach to Clinical Development Harrow takes a isciplined, risk-conscious approach to product development, with a clear focus on flawless exe: Low Clinical and Regulatory Risk Minimal Capital Investment » De-risked: Heavily biased toward * Capital efficient development of approved, near-ap
Slide 21: Product Development Pipeline
Product Developmeni Pipeline Compound Indication Stage of Development Potential Launch Procedural | ee “mm Uveitis, Visualization during 2028 vitrectomy A specific type of ce, Ocular Neoplasia 2029 =aN Invetlort Analyst Day | September2023 HARROW" kh
Slide 22: Next Steps For MELT-300
Next Steps For MELT-300 Agreement with U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment* (SPA) for the MELT-300 Phase 3 Study Covering: @ Study Design and Planned Analysis @ Study Statistical Approach & Primary and Secondary Endpoints FDA agreed that the Phase 3 study would “
Slide 23: Next Generation TRIESENCE
NGM os ee Next Generation TRIESENCE Opportunity: New product with ease of use for surgeons and stabilized supply chain Presentation change and formulation optimization of TRIESENCE in a prefilled syringe (PFS) format Same label as current TRIESENCE; will require filing a new NDA with a single pivota
Slide 24: CR-01 Conjunctival Delivery Device
Neer CR-01 (Conjunctival Delivery Device) Opportunity: Drug delivery device for treatment of rare disease oncology indication, a type of ocular neoplasia Harrow has entered into an agreement with a drug delivery company founded by Mark Humayun, MD, PhD (USC) and YC Tai, PhD (CalTech), securing the o
Slide 25: Melt Pharmaceuticals
Melt Pharmaceuticals Larry Dillaha, MD CEO, Melt Pharmaceuticals Maggie Jeffries, MD Procedural Sedation Expert Investor & Analyst Day | Sepiember 2029 HARROW’
Slide 26: Introduction to Melt Pharmaceuticals
Introduction to Melt Pharmaceuticals Larry Dillaha, MD CEO of Melt Pharmaceuticals Larry Dillaha, M.D. is an experienced executive with 20 years of experience in the pharmaceutical industry. Prior to joining Melt Pharmaceuticals as Chief Executive Officer in June 2021, he served as the Chief Medical
Slide 27: IV- and Opioid-Free Procedural Sedation
IV- and Opioid-Free Procedural Sedation Lead Drug Candidate: MELT-300 Fixed dose sublingual tablet combining 3 mg midazolam + 50 mg ketamine (non-opioid), two known and proven FDA-approved molecules in a novel form Technology Administration Dissolves in seconds under the tongue, using Easy, quick ab
Slide 28: Proprietary Product with Potential to Impact Many Markets
Neer Proprietary Product with Potential to Impact Many Markets Patents and Exclusivity Targets and Expansion T_) $6lssued U.S. Patents with additional patents Initial Target of Cataract Surgery “Q,|_ resulting from Phase 2 and Phase 3 data with the Potential to Expand pending (and patent restoration
Slide 29: MELT-300 Special Protocol Assessment
MELT-300 Special Protocol Assessment Agreement with U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment* (SPA) for the MELT-300 Phase 3 Study Covering: G Study Design and Planned Analysis @ Study Statistical Approach Gg Primary and Secondary Endpoints FDA agreed: + the MELT-300
Slide 30: MELT-300 is Statistically Superior to Midazolam Alone and Placebo
a MELT-300 is Statistically Superior to Midazolam Alone and Placebo Phase 3 Patients Achieving Adequate Sedation Without the Need for Rescue Medication 79% x 36% MELT-300 Midazolam 3mg SL Placebo = Topical numbing medication (69 total patients) {89 total patients) HARROW
Slide 31: MELT-300 Has a Favorable Safety Profile
NGS eee MELT-300 Has a Favorable Safety Profile G Favorable safety profile that was generally comparable to placebo MELT-300 G No severe adverse events High-Level Safety Profile* G No discontinuations due to adverse events No clinically meaningful differences in vital signs, ECGs, or neurocognitive
Slide 32: Reimbursement Should Drive Increased Adoption
Reimbursement Should Drive Increased Adoption Public and Private Payors* Transitional Pass-through Payment « Eligible for separate payment by Centers for Medicare & Medicaid Services (CMS) from a capitated fee + Transitional pass-through status (i.e., separately billable) under Medicare Part B for t
Slide 33: An Expert's Perspective on Procedural Sedation
An Expert's Perspective on Procedural Sedation Dr. Maggie Jeffries, MD, FASA Houston, TX Ambulatory Ophthalmic Anesthesia for Eye Center of Texas, Houston Eye Associates, Retina Consultants of Texas Medical Director, Memorial Hermann Surgery Center Kirby Glen President, Ophthalmic Anesthesia Society
Slide 34: Why sedation without an IV?
Why sedation without an IV? Why Not? Not all surgical sites have Frequent and persistent drug and access to IVs supply shortages 02 ] Difficult IVs = delays = lower efficiency = $§ © Risk is minimal with IV but still a risk Patients have IV anxiety and when given a choice, patients prefer oral © Opi
Slide 35: Why is sublingual superior to oral?
Why is sublingual superior to oral? (1) Narang N, Sharma J. Sublingual mucosa as a route for systemic dru Inter Dysphagia and malabsorption are prevalent - sublingual route bypasses the need for swallowing and gastric absorption Bypasses the hepatic first pass effect with the result being bioavailab
Slide 36: Why Midazolam and Ketamine combined?
Why Midazolam and Ketamine combined? The Ideal anesthetic....alleviates anxiety, causes amnesia, relieves/prevents pain, allows the patient to remain cooperative and lay still, provides cardiovascular stability, is cost effective, allows for rapid recovery, and has minimal side effects Opiates, whil
Slide 37: MELT-300 Label Expansion Potential
Neer MELT-300 Label Expansion Potential MELT-300's formulation has the Over 1 00,000, 000 potential to replace IV sedation in Total Estimated Annual Procedures (US) medical interventions such as emergency room procedures, dental, Dental (root canals) Colonoscopy Upper GI Endoscopy Plastic surgery, e
Slide 38: Commercial Vision
Commercial Vision Patrick Sullivan, Head of Commercial Investor & Analyst Day | Sepiember 2029 HARROW’
Slide 39: Introduction: Patrick Sullivan
Introduction Patrick Sullivan Head of Commercial 25 years of commercial leadership experience across U.S. and global markets in biotech, start-up, mid-sized, and global pharma organizations Expertise in commercialization planning, launch strategy, market development, go-to-market execution, and grow
Slide 40: Commercial Vision
Commercial Vision Market Leadership in Ophthalmology The Future of Ophthalmic Care Starts with Harrow + Establish Harrow as the leading U.S. ophthalmic pharmaceutical company and the pariner of choice for eye care professionals Driving Sustainable Growth with Discipline Scaling for Growth, Centered
Slide 41: Well-recognized conditions with significant opportunity to capture new growth
Well-recognized conditions with significant opportunity to capture new growth milion people in US diagnosed wi | milion US people affected by eye infections annually* (ct 2017 pp. 90-78, Mipfdeiorg/0 016 oo 201706038. 2. Oph HARROW
Slide 42: Commercial Summary
Commercial Summary Market Segment Portfolio Focus Commercial Priorities 1 ) Dry Eye Dry eye disease solution Depth, breadth, experience Pan-retina Strategic account activation, i biosimilar readiness Pe] | Suicat | Peri-operative Activate displacement strategy Targeted, scalable investment Partnersh
Slide 43: VEVYE Overview
VEVYE Overview Maria Lloyd, VP of Dry Eye Investor & Anal lyst Day | September 2025 HARROW
Slide 44: Introduction: Maria Lloyd
Introduction Maria Lloyd Vice President, Dry Eye * 20 years of ophthalmology experience, leading teams in large enterprise and startup environments + Last 15 years focus on promotion and launch of numerous eyecare products including Buy & Bill and recently leading all sales and marketing efforts for
Slide 45: Addressing Anterior Segment Inflammation & Dry Eye Disease
Addressing Anterior Segment Inflammation & Dry Eye Disease e vévye (cyclosporine ophthalmic solution) 01% J FDA-approved to treat the signs & symptoms of Dry Eye Disease Vision to become the #1 cyclosporine-based DED prescription and eventually, the #1 DED prescription in the US Harrow has a Flarex
Slide 46: VEVYE - A Best-in-Class Solution for Dry Eye Disease
VEVYE - A Best-in-Class Solution for Dry Eye Disease The first and only water-free cyclosporine to treat the signs and symptoms of dry eye disease In apre-clinical ex-vivo corneal penetration study, VEVYE's vehicle delivered ~22x more cyclosporine into the cornea than Restasis Rapid Onset — fastest
Slide 47: Category-Leading Target Profile
cae ee Category-Leading Target Profile* I Signs and symptoms of DED BID Schirmer Day 29 RTE RIDGES } miebor? | Signs and symptoms of DED aD Wee iodae Se eee RS BID Schirmer Day 180 EDS Day 428 84 iCFS Day 84 Tyrvaya™ & Signs and symptoms of DED BID Schirmer Day 28 VEVYE offers a best-in-class safety
Slide 48: VEVYE Access For All (VAFA)
VEVYE Access For All (VAFA) Eyecare professional prescribes VEVYE through specialty pharmacy Specialty pharmacy dispenses VEVYE Patient receives VEVYE regardless of insurance coverage for $0-$59 per bottle** Remove Access Barriers for Patients and Providers No prior authorization submission delays i
Slide 49: VEVYE Q2 2025 Market Share
VEVYE Q2 2025 Market Share Market Share as of Q2 2025* As of Q2 2025, VEVYE has captured 7.8% of 7.80% the total DED market, an increase of 2.6% yeu aad from Q1 2025 vs. Q2-25 Harrow’s primary strategic goal is - to become the number one most prescribed cyclosporine 5.207% In QI 2025, VEVYE surpasse
Slide 50: Experts Perspective of Dry Eye & VEVYE
Experts Perspective of Dry Eye & VEVYE Paul Karpecki, OD, FAAO Paul M. Karpecki, OD, FAO, received his Doctor of Optometry degree from Indiana University and completed @ fellowship in medical cornea and refractive surgery in Kansas City in affiliation with the Pennsylvania College of Optometry, now
Slide 51: Increasing Patient Population
Increasing Patient Population” In the U.S., every year 3M 800 GLAUCOMA : REFRA PATIENTS? A: SUR CATARACT CONTACT LENS SURGERIES! WEARERS* THE AVERAGE AMERICAN SPENDS =7 HRS A DAY HARROW
Slide 52: Symptoms
Symptoms Chronic dry eye disease is more than burning, itching, dryness, irritated and tired eyes 4A ey + DIFFICULTY REDUCTION IN woRK DIFFICULTY WEARING CONTACTS READING SPEEDS PRODUCTIVITY DRIVING AT NIGHT BLURRED VISION SENSITIVITY REDUCTION IN TO LIGHT QUALITY SLEEP Mesipesreen soe lrpovn ie alo
Slide 53: DED disrupts the tear film's natural balance
DED disrupts the tear film's natural balanceé Tear film instability can lead to inflammation and damage to the ocular surface?” Inflammation disrupts the ocular surface and increases symptoms of irritation and visual fluctuations’ Chronic Dry Eye Progression N\ a> = Comeal surface Tear film damage i
Slide 54: The Common Denominator?
The Common Denominator? “= Ah_ia-> MA \A 00k 1 Hoa 13-1307 0 La dy. 2251194728 KOLPresentation | September 2029 HARROW"
Slide 55: Common Options on the Market
Common Options on the Market Comeal surface Tear flim damage: instability Infammation Hyperosmolarity
Slide 56: Current DED Prescription Treatments Show High Discontinuation Rates
Current DED Prescription Treatments Show High Discontinuation Rates Treatment discontinuation rate at 12 months!>!¢ = Discontinue = Remain on Therapy (N=9,772) KOLPresentation | September 2029 HARROW"
Slide 57: Cyclosporine Targets Biomarkers Throughout the Inflammation Cascade
Cyclosporine Targets 5 Biomarkers Throughout the Inflammation Cascade CYCLOSPORINE PREVENTS ACTIVATION OF NF-KB Cyclosporine inhibits activation of nf-Kb, effectively diminishing pro-inflammatory cytokines such as!!: Cyclosporine (CsA) has been used in a v number of FDA approved prescription treatme
Slide 58: First and Only ...
First and Only ... 2 3 Cyclosporine Water-free dissolved in a Cyclosporine semifluorinated alkane
Slide 59: Continuous VAS Improvement
Continuous VAS Improvement Through Week 56 Discomfort (Dryness) VAS Scores o 4 8 2 26 3 2 5 ss . In a 52-week open label extension study (n=200), VEVYE demonstrated continuous symptom improvements Terese: pet tstepb ssDNA Sone ns sexo ete dey el cnevaarhes lcd cmon om ‘as measured by the Visual Anal
Slide 60: Patient Symptom Improvement
Patient Symptom Improvement All measured symptoms showed improvement throughout the 52-week study?” @ © S&S 4 DRYNESS BLURRED VISION FREQUENCY OF AWARENESS OF DRYNESS DRY EYE gi + y) READING SPEEDS LOOKING AT FLUCTUATING VISION. DRIVING AT NIGHT SCREENS KOLPresentation | September 2023 HARROW"
Slide 61: With VEVYE
WITH VEYVE® 99.87% PATIENTS EXPERIENCED NO OR MILD INSTILLATION SITE PAIN!”
Slide 62: Case Study
Case Study 1 56-year-old white female Presenting for comprehensive examination » Rediitchy eyelids and fluctuating vision » Stopped wearing CLs due to blurry vision BCVA: 20/25-1 OD and 20/25-1 OS SPEED: 21/28 Current medications + Flaxseed oil, fluticasone, preservative-free lubricating ointment Pr
Slide 63: Case Study
CASE STUDY 1 Before After ~~ VEVYE treatment - OS 1 month of VEVYE - OS i BCVA: 20/20 OU Successfully resumed CL wear Quality of vision improved Continue VEVYE Ben Gaddie OD, Louisville KY HARROW KoLPresentation | s
Slide 64: Case Study
CASE STUDY 1 Before After VEVYE treatment - OD 1 month of VEVYE- OD BCVA: 20/20 OU Successfully resumed CL wear Quality of vision improved Continue VEVYE Ben Gaddie OD, Louisville KY HARROW KoLPresentation | s
Slide 65: Access For All Programs
Access For All Programs Prashanth Annavajjhala, MD Chief of Staff to the CEO Investor & Analyst Day | Sepiember 2029 HARROW’
Slide 66: Introduction: Prashanth Annavajjhala
Introduction Prashanth Annavajjhala, MD Chief of Staff to the CEO Prashanth S. Annavajjhala joined Harrow in September 2023 and has served as Chief of Staff to Harrow's CEO, Mark L. Baum, since July 2025. Prashanth has over 10 years of experience in Market Access, Healthcare Strategy, and Product Co
Slide 67: VEVYE Access For All (VAFA)
my VEVYE Access For All (VAFA) vevye yevye Dr. smith Dr. Smith BA ppolocare: VAFA Is pharmacy agnostic The crifical factor Is ensuring optimal prescriber and patient experience by using a Harrow pharmacy pariner and leveraging their respective pharmacy networks that adhere to the VAFA business rules
Slide 68: Harrow Access For All (HAFA)
Harrow Access For All (HAFA) Building on the Success of VEVYE Access for All Harrow Portfolio Branded Products (Q4 2025) “= Generic (H1 2026) Compounded (2027) = Available Through a Single Trusted Access Point Accessible and Affordable for All Patients ‘The Amazon for Ophthalmology’ A seamless and u
Slide 69: TRIESENCE Expansion + BYQLOVI Launch
TRIESENCE Expansion + BYQLOVI Launch Chad Brines, VP of Surgical Portfolio
Slide 70: Introduction: Chad Brines
Introduction Chad Brines Vice President, Surgical Portfolio * Over 20 years of medical device & pharmaceutical sales experience, including Novartis, Stryker and J&J * Led the execution of the go-to-market strategy to successfully launch DEXTENZA® (a post-ocular surgery steroid) at Ocular Therapeutix
Slide 71: Focused on the Ocular Surgery Market
Neer Focused on the Ocular Surgery Market Over 7M Ocular Surgeries Performed Harrow is strategically focused on the ocular surgery Annually in the US market as it represents one of the largest, fastest- growing, and most critical segments in eye care Breakdown of Ocular Surgeries NV Large and growin
Slide 72: Building a World-Class Surgical Portfolio
Building a World-Class Surgical Portfolio oe Establish TRIESENCE as a first- line treatment option for ocular ILEVRO. (riamcinolone aceonife inflammation unresponsive “penn injectable suspension) "0 topical steroids ~ Compimentary : products to support a s! mg Launch in @4 2025 Nevanac complete offe
Slide 73: Focusing on the Ocular Inflammation Market
Focusing on the Ocular Inflammation Market Focus on establishing TRIESENCE as a first-line treatment option for ocular inflammation unresponsive to topical steroids + FDA-approved, on-label, preservative-free option + TRIESENCEis the most affordable FDA-approved injectable ocular steroid + Patient's
Slide 74: BYQLOVI - Best-in-Class Steroid
NGM os ee BYQLOVI - Best-in-Class Steroid BYQLOVI" (clobetasol propionate A recent acquisition leveraging Harrow’s ophthalmic suspension) 0.05% commercial infrastructure Description: + BYQLOVI is an FDA-approved steroid to treat inflammation and pain after ocular surgery + Super potent and unique st
Slide 75: Commercial Focus
Commercial Focus * Building a commercial team for the surgical portfolio * Expected to be fully staffed in early 2026 * TRIESENCE expansion into the ocular inflammation market will begin in Q4 2025, with initial impact seen in early 2026 * Anexperienced leader focused on the surgical branded portfol
Slide 76: Retina Product Portfolio
Retina Product Portfolio Aly Harrison, VP of Retina Portfolio Investor & Analyst Day | September 20: 2 HARROW
Slide 77: Introduction: Aly Harrison
Introduction Aly Harrison Vice President, Retina Portfolio * 30+ years in biotech specialty pharmaceuticals + Last 13 years with Market Access experience across Field Reimbursement, Payer Strategy, Contracting, Patient Support Services, GPO Programs, Trade and Distribution Management. Commercializat
Slide 78: Building a Leading Retina Franchise
Building a Leading Retina Franchise Retina market leader with broadest portfolio in large markets Harrow is redefining retina care — building the largest, most comprehensive portfolio of treatments to empower physicians and transform outcomes for millions of patients Harrow’s unique infrastructure i
Slide 79: Recent Launch of Harrow Cares HUB
Recent Launch of Harrow Cares HUB THEEZO. —tiansioexnie injectable suspension) ‘yi * Partnered with Cencora for reimbursement support through Harrow Cares HUB for HEEZO \ fey) HARROW and TRIESENCE CARES Provides customer with reimbursement confidence and support Harrow Cares helps you use TRIESENCE
Slide 80: IHEEZO Overview
IHEEZO Overview Sterile, single-patient-use, physician-administered, ophthalmic gel preparation for ocular surface anesthesia, approved by the FDA September 2022 IHEEZO clinical studies EZO (horaprocaine HCl ph First approved use in the U.S. ophthalmic market of chloroprocaine hydrochloride. First b
Slide 81: Slide 81
Slide 82: Slide 82
Slide 83: Slide 83
Slide 84: Slide 84
Slide 85: Slide 85
Slide 86: Slide 86
Slide 87: Slide 87
Slide 88: Slide 88
Slide 89: Slide 89
Slide 90: Slide 90
Slide 91: Slide 91
Slide 92: Slide 92
Slide 93: Slide 93
Slide 94: Slide 94
Slide 95: Slide 95
Slide 96: Slide 96
Slide 97: Slide 97
Slide 98: Slide 98
Slide 99: Slide 99
Slide 100: Slide 100
Slide 101: Slide 101
Slide 102: Slide 102
Slide 103: Slide 103
Slide 104: Slide 104
Slide 105: Slide 105
Slide 106: Slide 106
Slide 107: Slide 107
Slide 108: Slide 108
Slide 109: Slide 109
Slide 110: Slide 110
Slide 111: Slide 111
Slide 112: Slide 112
Slide 113: Slide 113
Slide 114: Slide 114
Slide 115: Slide 115
Slide 116: Slide 116
Slide 117: Slide 117